Plain-English translation of NCT06692725 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether a shorter chemotherapy regimen works as well as a longer one for treating triple negative breast cancer. Both groups receive taxane-based chemotherapy combined with carboplatin and a PD-1 inhibitor (an immunotherapy drug). The key difference is that one group receives an additional anthracycline drug, while the other does not—researchers want to see if the simpler approach is just as effective.
Triple negative breast cancer is an aggressive form of cancer that doesn't respond to certain common hormone and targeted therapies. This trial exists to find out whether patients can achieve the same treatment success with a de-escalated (simplified) chemotherapy regimen, potentially reducing side effects while maintaining effectiveness.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive one of two chemotherapy regimens combined with an immunotherapy medication, given at the hospital over several months. One group receives taxane chemotherapy plus carboplatin for 6 cycles with the immunotherapy drug; the other group receives taxane plus carboplatin for 4 cycles, followed by anthracycline chemotherapy for 4 cycles, also with the immunotherapy drug. Researchers will monitor your response through imaging and tissue samples to see how well the cancer responds to treatment.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
China